Table 1
Open in new tab

Prevalence of genetically defined thrombophilia and the relative risk for venous thromboembolism in the normal population and in pregnancy

Factor V Leiden hetero-/homozygousProthrombin G20210A mutation hetero-/homozygousCompound factor V Leiden and prothrombin G2021 mutationAntithrombin deficiencyProtein C deficiencyProtein S deficiencyHyperhomo cysteinemia
Prevalence in the normal population2–7%/0.06–0.25%0.7–4%/rare0.1%0.02%0.2%0.03–0.13%5–10%
Relative risk of first VTE5–7/6.8–19.32–3/2.2–20.71.1–515–2015–2015–201.5–2.5
After termination of anticoagulation1.4/1.81.4/not enough data2.71.9–2.61.4–1.81–1.42.5
Relative risk of pregnancy complication1–2.60.9–1.3—1.3–3.61.3–3.61.3–3.6—
Factor V Leiden hetero-/homozygousProthrombin G20210A mutation hetero-/homozygousCompound factor V Leiden and prothrombin G2021 mutationAntithrombin deficiencyProtein C deficiencyProtein S deficiencyHyperhomo cysteinemia
Prevalence in the normal population2–7%/0.06–0.25%0.7–4%/rare0.1%0.02%0.2%0.03–0.13%5–10%
Relative risk of first VTE5–7/6.8–19.32–3/2.2–20.71.1–515–2015–2015–201.5–2.5
After termination of anticoagulation1.4/1.81.4/not enough data2.71.9–2.61.4–1.81–1.42.5
Relative risk of pregnancy complication1–2.60.9–1.3—1.3–3.61.3–3.61.3–3.6—

Adapted from ref.8–11

VTE, venous thromboembolism.

Table 1
Open in new tab

Prevalence of genetically defined thrombophilia and the relative risk for venous thromboembolism in the normal population and in pregnancy

Factor V Leiden hetero-/homozygousProthrombin G20210A mutation hetero-/homozygousCompound factor V Leiden and prothrombin G2021 mutationAntithrombin deficiencyProtein C deficiencyProtein S deficiencyHyperhomo cysteinemia
Prevalence in the normal population2–7%/0.06–0.25%0.7–4%/rare0.1%0.02%0.2%0.03–0.13%5–10%
Relative risk of first VTE5–7/6.8–19.32–3/2.2–20.71.1–515–2015–2015–201.5–2.5
After termination of anticoagulation1.4/1.81.4/not enough data2.71.9–2.61.4–1.81–1.42.5
Relative risk of pregnancy complication1–2.60.9–1.3—1.3–3.61.3–3.61.3–3.6—
Factor V Leiden hetero-/homozygousProthrombin G20210A mutation hetero-/homozygousCompound factor V Leiden and prothrombin G2021 mutationAntithrombin deficiencyProtein C deficiencyProtein S deficiencyHyperhomo cysteinemia
Prevalence in the normal population2–7%/0.06–0.25%0.7–4%/rare0.1%0.02%0.2%0.03–0.13%5–10%
Relative risk of first VTE5–7/6.8–19.32–3/2.2–20.71.1–515–2015–2015–201.5–2.5
After termination of anticoagulation1.4/1.81.4/not enough data2.71.9–2.61.4–1.81–1.42.5
Relative risk of pregnancy complication1–2.60.9–1.3—1.3–3.61.3–3.61.3–3.6—

Adapted from ref.8–11

VTE, venous thromboembolism.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close